NASDAQ:BRTX
BioRestorative Therapies, Inc. Stock News
$1.26
-0.0300 (-2.33%)
At Close: May 21, 2024
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
09:00am, Wednesday, 15'th May 2024
MELVILLE, NY / ACCESSWIRE / May 15, 2024 / As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to
BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript
07:08pm, Tuesday, 14'th May 2024
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Stephen Kilmer - Head of Investor Relations Lance Alstodt - President, Chief
BioRestorative Therapies Provides First Quarter 2024 Business Update
04:10pm, Tuesday, 14'th May 2024
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-b
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
07:30am, Wednesday, 08'th May 2024
— New therapeutic candidate developed using Company's patented ThermoStem ® platform —
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
04:15pm, Tuesday, 30'th Apr 2024
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity -
— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform —
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
07:45am, Tuesday, 16'th Apr 2024
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity —
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
07:45am, Monday, 01'st Apr 2024
MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
04:15pm, Monday, 11'th Mar 2024
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based ther
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
09:15am, Wednesday, 14'th Feb 2024
MELVILLE, NY / ACCESSWIRE / February 14, 2024 / BioRestorative Therapies (NASDAQ:BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease
MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
07:30am, Monday, 05'th Feb 2024
— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 20
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
07:30am, Thursday, 01'st Feb 2024
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at 8:30